Nicole Lambert - Sep 25, 2021 Form 4 Insider Report for MYRIAD GENETICS INC (MYGN)

Role
Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.
Signature
By: Nathan A. Smith For: Nicole Lambert
Stock symbol
MYGN
Transactions as of
Sep 25, 2021
Transactions value $
-$492,536
Form type
4
Date filed
9/27/2021, 09:13 PM
Previous filing
Sep 23, 2021
Next filing
Oct 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MYGN Common Stock Tax liability -$43.7K -1.31K -0.68% $33.31 192K Sep 25, 2021 Direct F1
transaction MYGN Common Stock Tax liability -$114K -3.43K -1.79% $33.31 188K Sep 26, 2021 Direct F1
transaction MYGN Common Stock Sale -$335K -10.1K -5.37% $33.10 178K Sep 27, 2021 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. The number of shares of Myriad common stock withheld was determined based on the closing price of Myriad common stock on September 24, 2021.
F2 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.43 to $33.62, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.